2003–2011 yılları içerisinde Cumhuriyet Üniversitesi Tıp Fakültesi Hastanesi’nde anti HCV görülme sıklığı ve pozitifliklerin yıllara göre karşılaştırılması

Abstract

Amaç: Bu çalışmada, 2003–2011 yılları arasında Cumhuriyet Üniversitesi Araştırma ve Uygulama Hastanesi’ne başvuran hastalardan hepatit şüphesiyle mikrobiyoloji laboratuvarına gönderilen kan örneklerinde HCV antikorunun görülme sıklığı ve yıllar arasındaki dağılımların karşılaştırılması amaçlanmıştır. Yöntemler: Bu çalışmada; 2003–2011 yıllarını kapsayan dokuz yıllık dönemde Cumhuriyet Üniversitesi Tıp Fakültesi Uygulama ve Araştırma Hastanesine başvuran hastaların anti HCV sonuçları laboratuvar kayıtlarından geriye dönük olarak incelenmiştir. Bulgular: 2003–2011 yılları arasında mikrobiyoloji laboratuvarına gönderilen toplam 255.764 kan örneğinin 5085 %1,9 ’inde anti HCV testi pozitif bulunmuştur. Bulunan HCV antikoru oranları yıllara göre karşılaştırıldığında ise oranların %1,7 ile %2,3 arasında değiştiği görülmüştür. Sonuç: HCV enfeksiyonunun güncelliğini sürdürmekte olduğu görülmektedir. Hastalığın kontrol altında tutulabilmesi için verilerin sürekli olarak güncellenmesi gerekmektedir. Çalışmanın bu konudaki literatüre katkı sağlayacağı düşünülmektedir

Keywords

• Anti HCV pozitif, anti HCV testi, HCV antikoru, seroprevalans

Anti HCV frequency and comparison of its positiveness by year obtained of Cumhuriyet University Medical Faculty Hospital between 2003-2011

Abstract

Objective: In this study, it is aimed to compare the prevalance of HCV antibody in hepatitis suspected blood samples taken from the patients applying to the Research and Practice Hospital of Cumhuriyet University between the years 2003 and 2011 and the rates of HCV antibody in those years. Methods: In this study, the anti HCV results of patients app; ed to the Research and Practice Hospital of Cumhuriyet University between the years 2003 and 2011 are investigated according to the retroactive records of laboratory. Results: In 5085 blood samples 1.9% of 255764 in total sent to the microbiology laboratory between the years 2003 and 2011, anti HVC test is found positive. Of the total of 255.764 samples sent to the mictobiology laboratory between the years 2003 and 2011, 5085 1.9% samples were found positive. When the rates of HCV antibody were calculated within the years, it was determined that notes varied between 2.3% and 1.7%. Conclusion: It can be seen from the data found in this study that HCV infection maintains its up-to-dateness. The data should be updated in order to keep the illness under control constantly. It is thought that study may contribute the literature on this subject.

Keywords

• Anti HCV positive, anti HCV test, HCV antibody, seroprevalence

References

1. Erenmemişoğlu A, Tekol Y, Kartal M, Kurucu S. The use of a smokeless tobacco in our country “maraşotu” Second International Symposium of Pharmaceutical Sciences. Ankara-Turkey, June, 11- , 1991.
2. Idris AM, Ibrahim YE, Warnakulasuriya KA, Cooper DJ, Johnson NW, Nilsen R. Toombak use and cigarette smoking in the Sudan: estimates of prevalence in the Nile state. Prev Med, 1998; (4): 597-603.
3. Ibrahim SO, Vasstrand EN, Johannessen AC, Idris AM, Magnusson B, Nilsen R, et al. Mutations of the p53 gene in oral squamous-cell carcinomas from Sudanese dippers of nitrosamine-rich toombak and non-snuff-dippers from the Sudan and Scandinavia. Int J Cancer, 1999; 81(4): 527-34.
4. Sopori LM, Kozak W. Immunomodulatory effects of cigarette smoke. J Neuroimmunol, 1998; 83, 56.
5. Ozkul Y, Erenmemisoglu A, Cucer N, Menevse A, Saatci CA. Sister-chromatid exchange inducing effect of smokeless tobacco using on T-lymphocyte chromosomes. Mutat Res, 1995; 334(2): 209-12.
6. Erenmemisoglu A, Ustun H, Kartal M. Carcinoma of buccal mucosa in smokeless tobacco users: a preliminary study of the use of cytology for early detection. Cytopathol, 1995; 6(6): 403-8.
7. Idris AM, Ibrahim SO, Vasstrand EN, Johannessen AC, Lillehaug JR, Magnusson B, et al. The Swedish snus and the Sudanese toombak: are they different? Oral Oncol, 1998; 34(6): 558-66.
8. Holt PG. Immune and inflammatory function in cigarette smokers. Thorax, 1987; 42: 241-9. Gulsvik A, Fagerhol MK. Smoking and immunoglobulin levels. Lancet, 1979; 1: 449.

9. Tollerud DJ, Clark YW, Brown LM, Nevla’nd CY, Mann DL, Pankiw-Trost LK, et al. Association of cigarette smoking with decreased numbers of circulating natural killer cells. Am Rev Respir Dis, Tollerud DJ, Clark JW, Brawn LM, Neuland CY, Mann DL, Pankiw-Trast LK, et al. The effects of cigarette smoking on T-cell subsets. a population-based survey of healthy caucasians. Am Rev Respir Dis, ; 139(6): 1446-51.
10. Buckley CE, Darsey FC. Serum immunoglobulin levels throughout the life span of healthy man. Ann Intern Med, 1971; 75: 673-82.
11. Tollerud DJ, Clark JW, Brown LM, Neuland CY, Pankiw-Trast LK, Blattner WA, et al. The influence of age, race, and gender on peripheral blood mononuclear cell subsets in healthy nonsmokers. J Clin Immunol, 1989; 9(3): 214-22.
12. Goud SN, Zhang L, Kaplan AM. Immunostimulatory potential of smokeless tobacco extract in in vitro cultures of murine lymphoid tissues. Immunopharmacol, 1993; 25(2): 95-105.
13. Lindemann RA, Park NH. Inhibition of human lymphokine-activated killer activity by smokeless tobacco(snuff) extract. Arch Oral Biol, 1988; 33(5): 21.
14. Kılıçturgay K. İmmünoloji. 3.Baskı, İstanbul; Güneş Nobel Kitabevi, 2003; 15-51.
15. Belkastro AN, Arthur GD, Albisser RA, Raj DA. Heart, liver, and skeletal muscle myeloperoxidase activity during exercise. J Appl Physiol, 1996; 80: –5.
16. Fry RW, Morton AR, Keast D. Biological responses to overload trainin in endurance sports. Eur J Appl Physiol, 1992; 64: 335–44.
17. Larramendy LM, Knuutila S. Increased frequency of micronuclei in B and T8 lymphocytes from smokers. Mutat Res, 1991; 259: 189-95.
18. Moszczynski P, Zabinski Z, Moszczynski P Jr, et al. Immunological findings in cigarette smokers. Toxicol Lett, 2001; 118(3): 121-7.
19. Tollerud DJ, Clark JW, Brawn LM, Neuland CY, Mann DL, Pankiw-Trast LK, et al. T cell subsets in healthy black smokers and nonsmokers. Evidence for ethnic group as an important respanse modifier. Am Rev Respir Dis, 1991; 144: 612-6.
20. Öktem MA. Hantavirüs ve kene ile bulaşan ensefalit virüsü infeksiyonları. ANKEM Derg, 2009; 23: 8.
21. Vapalahti O, Mustonen J, Lundkvist A. Hantavirus infections in Europe. Lancet Infect Dis, 2003; 3: –61.
22. Heyman P. Situation of hantavirus infections and haemorrahagic fever with renal syndrome in European countries as of December 2006. Euro Surveil, 2008;13 (28): 1–7.
23. Ertek M, Buzgan T. An outbreak caused by hantavirus in the Black Sea region of Turkey. Euro Surveill, 2009; 14 (20): 1–2.
24. Kaya S, Yılmaz G, Erensoy S, Yağçı Çağlayık D, Uyar Y, Köksal I. Hantavirus infection: two case reports from a province in the Eastern Blacksea Region, Turkey. Mikrobiyol Bul, 2010; 44 (3): 479–87.
25. Öngürü P, Yılmaz S, Akıncı E, Özdemir B, But A, Yetkin A, et al. Hemorrhagic fever with renal syndrome: two case reports. Turk Hij Den Biyol Derg, 2011; 68 (1): 35–9.
26. Cole JR, Sulzer CR, Pursell AR. Improved microtechnique for the leptospiral microscopic agglutination test. APPL Microbiol, 1973; 25: –81.
27. Weidmann M, Sanchez-Seco MP, Sall AA, Ly PO, Thiongane Y, Lô MM, et al. Rapid detection of important human pathogenic phleboviruses. J Clin Virol, 2008; 41 (2): 138-42.
28. Heyman P, Cochez C, Korukluoglu G, Gözalan A, Uyar Y, Lundkvist A. Bridging continents; hantaviruses of Europe and Asia minor. Turk Hij Den Biyol Derg, 2011; 68 (1): 41-8. WHO. hantavirus, and alkhurma haemorrhagic fever, as emerging infectious diseases apps.who.int/gb/ ebwha/pdf_files/ EB127/B127_3-en.pdf. fever,
29. Laakkonen J, Kallio-Kokko H, Oktem MA, Blasdell K, Plyusnina A, Niemimaa J, et al. Serological survey for viral pathogens in Turkish rodents. J Wildl Dis, 2006; 42 (3): 672-6.
30. Oncul O, Atalay Y, Onem Y, Turhan V, Acar A, Uyar Y, et al. Hantavirus infection in Istanbul, Turkey. Emerg Infect Dis, 2011; 17 (2): 303–4.
31. Kuchuloria T, Clark DV, Hepburn MJ, Tsertsvadze T, Pimentel G, Imnadze P, et al. Hantavirus infection in the Republic of Georgia. Emerg Infect Dis, 2009; (9):1489–91.
32. Papa A, Antoniadis A. Hantavirus infections in Greece an update. European J Epidemiol, 2001; : 189–94.
33. Çelebi G. Hantavirüs enfeksiyonları. Klinik Gelişim, ; 23 (3): 40–4. Nanoteknolojiden nanogenotoksikolojiye: kobalt-krom nanopartiküllerinin genotoksik etkisi From nanotechnology to nanogenotoxicology: genotoxic effect of cobalt-chromium nanoparticles Zülal ATLI-ŞEKEROĞLU1 Thrall JH. Nanotechnology and medicine. Radiology, 2004; 230: 315-8.
34. Kuzma J, Priest S. Nanotechnology, risk, and oversight: learning lessons from related emerging technologies. 2010; Risk Anal, 30 (11): 1688-98.
35. Gupta J. Nanotechnology applications in medicine and dentistry. J Investig Clin Dent, 2011; 2: 81-8.
36. Syed S, Zubair A, Frieri M. Immune response to nanomaterials: implications for medicine and literature review. Curr Allergy Asthm Rep, 2013; 13 (1): 50-7.
37. Gök H. Fiziksel tıp ve rehabilitasyon uzmanlarının nanoteknolojiden beklentileri. Türk Fiz Tıp Rehabilitasyon Derg, 2007; 53 (2): 13-7.
38. Drexler KE. Nanotechnology: from Feynman to Funding. Bull Sci Technol Soc, 2004; 24 (1): 21-7.
39. Kocaefe Ç. NANOTIP: Yaşam bilimlerinde nanoteknoloji uygulamaları. Hacettepe Tıp Derg, ; 38: 33-8. Fu L, Cao L, Liu Y, Daoban Z. Molecular and nanoscale materials and devices in electronics. Adv Colloid Interface Sci, 2004; 111: 133–57. http://www.tubitak.gov.tr/tubitak_content_files/ vizyon, 2023 (14.02.2012).
40. Araştırmacı olarak bulunduğum ‘Kobalt-Krom Nanopartiküllerin İnsandaki Genotoksisitesi’ adlı proje kapsamındaki yurt dışı desteği nedeniyle TÜBİTAK’a teşekkür ederim. Res. 1998; 31: 1345-8.
41. Miao XR, Gao XF, Wu JX, Lu ZJ, Hunang ZX, Li XQ, et al. Bilateral down regulation of Nav 1.8 in dorsal root ganglia of rats with bone cancer pain induced by inoculation with walker 256 breast tumor cells. BMC Cancer, 2010; 10:216.
42. Novaes MRCG, Lima LAM, Souza MV. Efeitos farmacológicos da suplementação dietética com L-arginina a 6% em tumores experimentais. Rev Metabol Nutr, 2003; 7(2):52-6.
43. Lan LS, Ping YJ, Na WL, Miao J, Cheng QQ, Ni MZ, et al. Down-regulation of toll-like receptor 4 gene expression by short interfering RNA attenuates bone cancer pain in a rat model. Ann Mol Pain, ; 6: 2. Earle WR. A study of the walker rat mammary carcinoma 256, in vivo and in vitro. Am J Cancer Res, 1935; 24: 566-612.
44. Fisher ER, Fisher, B. Electron microscopic, histologic and histochemical features of the walker carcinoma. Cancer Res, 1961; 21: 527-30.
45. Guaitani A, Recchia M, Carli M, Rocchetti M, Bartosek I, Garattini S. Walker carcinoma 256: a model for studies on tumor anorexia and cachexia. Oncology, 1982; 39:173-8.
46. Morano JA, Cordeiro N, Guimarães SB, Fechine- Jamacaru FV, Vasconcelos PR, Moraes Filho MO. Experimental model of ultrasound thermotherapy in rats inoculated with walker-236 tumor. Acta Cir Bras, 2012; 27(1):13-7.
47. Camargo CA, da Silva ME, da Silva RA, Justo GZ, Gomes-Marcondes MC, Aoyama H. Inhibition of tumor growth by quercetin with increase of survival and prevention of cachexia in walker 256 tumor-bearing rats. Biochem Biophys Res Commun, ; 406(4): 638-42. Mattos MCFI, Montenegro MR, Silva CRV. Walker carcinossarcoma: pathology, microscopic and ultrastructural features of the tumoral circulating cells. Ciên Cult, 1980; 32(7): 849-57.
48. Rettori O, Vieira- Matos NA, Gontijo JA. Reduced renal sodium excretion in walker 256 tumor- bearing rats. APPTLA, 1996; 46: 111-8.
49. Simpkins H, Lehman JM, Mazurkiewicz JE, Davis BH. A morphological and phenotypic analysis of walker 256 cells. Cancer Res, 1991; 51(4): 1334-8.
50. Hester JE, Fee WE. Effect of arginine on growth of squamous cell carcinoma in the c3h/km mouse. Arch Otolaryngol Head Neck Surg, 1995; 121(2): 6.
51. Idris AI, Libouban H, Nyangoga H, Landao-Bassonga E, Chappard D, Ralston SH. Pharmacologic inhibitors of ikappa B kinase suppress growth and migration of mammary carcinosarcoma cells in vitro and prevent osteolytic bone metastasis in vivo. Mol Cancer Ther, 2009; 8(8): 2339-47.
52. Badraoui R, Blouin S, Moreau MF, Gallois Y, Rebai T, Sahnoun Z, et al. Effect of alpha tocopherol acetate in walker 256/B cells-induced oxidative damage in a rat model of breast cancer skeletal metastases. Chem Biol Interact, 2009; 182(2-3): 105.
53. Freire-Garabal M, Nuñez MJ, Pereiro D, Riveiro P, Losada C, Fernandez-Rial JC, et al. Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci, 1998; (2): 31-8.
54. Morrison SD. Water Intake and exchange and hydration of rats during growth of walker 256 carcinoma. J Nat Canc Inst, 1971; 46(4): 825-9.
55. Ye SL, Istafan NW, Driscoll DF, Bistrian BR. Tumor and host response to arginine and branched chain amino acid enriched total parenteral nutrition. Cancer, 1992; 69(1): 261-70.
56. Camargo CA, Gomes-Marcondes MC, Wutzki NC, Aoyama H. Naringin inhibits tumor growth and reduces interleukin-6 and tumor necrosis factor α levels in rats with walker 256 carcinosarcoma. Anticancer Res, 2012; 32(1): 129-33.